Extranodal natural killer/T cell lymphoma (ENKTL) is an EBV-associated and highly aggressive subtype of non-Hodgkin lymphoma. Most patients are distributed in Asia and South America, and advanced-stage patients have poor prognosis. Reports on research progress of ENKTL in the 58th American Society of Hematology Annual Meeting covered multiple respects which range from basic research to clinical prognosis and treatment: further study on pathogenesis of ENKTL is developing based on high-throughput sequence, and new prognostic index system can help to stratify patients more exactly; what's more, novel regimens make more benefits to the clinical efficacy and safety of ENKTL patients.

Marginal zone lymphoma (MZL) accounts for approximately 10 % of non-Hodgkin lymphoma (NHL). It can be divided into three specific entities:extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL). MALT lymphoma is the most frequent overall, representing 7.5 % of all NHLs. Reports on research progress of MZL in the 58th American Society of Hematology Annual Meeting covered multiple respects which ranged from basic research to clinical prognosis and treatment. Based on the technology such as flow cytometry, cytogenetics and FISH, further study on pathogenesis of MZL is developing, and new prognostic index system can help to stratify patients more exactly and give a guidance to treatment. What's more, the change of therapy and new drugs will benefit to the clinical efficacy and safety of MZL patients.

Peripheral T-cell lymphoma (PTCL) is a relatively common subtype of non-Hodgkin lymphoma in China. PTCL is clinically highly aggressive, and it progresses rapidly. The current treatment methods are ineffective and the overall prognosis is poor. The 62nd American Society of Hematology Annual Meeting reported on the progress of PTCL molecular targeted therapy and immunotherapy, including programmed death receptor 1/programmed death receptor ligand 1 antibodies, JAK inhibitors, brentuximab vedotin, etc. These novel drugs bring a better prospect for patients.

Chronic lymphocytic leukemia (CLL) is an oncologic disease with clonal proliferation of lymphocytes. In recent years, great advances have been made in the basic and clinical research of CLL. The 62nd American Society of Hematology Annual Meeting in 2020 presented a detailed report on the latest advance in basic research on these diseases, providing a deeper understanding of how CLL occurs and develops, and playing a guidance role in the clinical treatment.

Aim To develop a model for screening DPPIV inhibitor from Chinese Herbal medicine.Methods With Gly-Pro-PNA as a substrate,DPPIV activity was assayed by the chromogenic substrate.The concentration of DPPIV and Gly-Pro-PNA,temperature,pH and reaction time were optimized.Results The optimal enzymatic reaction system was as follows:DPPIV 0.5 U?L-1,Gly-Pro-PNA 0.262 ?mol?L-1,37℃,pH 8.2,reaction for 60 min.Further more,many kinds of herbal abstracts were screened and some had the DPPIV inhibitory function,such as Leech,Poria cum Radix Pini and Buddleja officinalis Maxim.Conclusion The model can be used to screen for DPPIV inhibitors in vitro.

Mantle cell lymphoma (MCL),as a kind of highly aggressive non-Hodgkin's lymphoma,is characterized by malignant B cell infiltration of lymph node,gastrointestinal tract and bone marrow.Patients suffering from MCL are prone to drug resistance or progression of disease.The 55th ASH annual meeting about MCL explored all aspects.In preclinical research aspects:new mutations including ATM,POT1 and tumor microenvironment further improved the pathogenesis mechanism of MCL.In prognostic indicators,minimal residual disease detected by molecular techniques and whole genome methylation analysis provided new tools for monitoring MCL prognosis and curative effect to guide further risk stratification and individual treatment.Exploration of high effective and low toxic side effective treatment strategies for elderly MCL patients has become a major focus of the meeting.Chemoimmunotherapy including Lenalidomide,bendamustine,rituximab and autologous stem cell transplantation provide more options for the treatment of elderly MCL patients.Novel drugs such as ibrutinib,ABT-199 and MLN8237 have shown encouraging results in preclinical trials which provide new hope for MCL patients.

ObjectiveTo investigate the protein expressions of PTEN and p-Akt in Kaposi's sarcoma (KS) tissue and their significance in the development of KS.MethodsThe EnVision two-step method was used to detect the expressions of PTEN and p-Akt proteins in tissue specimens from the lesions of 17 patients with KS and from the normal skin of 17 normal human controls.ResultsPTEN and P-Akt were mainly expressed in the cytoplasm of cells.No significant difference was observed in the positivity rate of PTEN [76.5％(13/17)vs.88.2％(15/17),P＞ 0.10] between the KS and control specimens.p-Akt was expressed in all(100％) of the 17 KS specimens,but in none of the control specimens.ConclusionThe abnormal expression of PTEN protein may play a certain role in the development of KS.

Next generation sequencing (NGS) has been applied in scientific research and clinical practice of mature lymphoid malignancies. The applications of NGS in the study of pathogenesis, treatment and prognosis evaluation, mechanisms of resistance to treatment in lymphoid malignancies have been reported in the 57th American Society of Hematology (ASH) annual meeting. This article summarized the advances in the use of NGS in mature lymphoid malignancies by reviewing several representative reports.

Chronic lymphocytic leukemia (CLL) is an incurable B cell chronic lymphoproliferative disorder with a highly heterogeneous clinical course.The malignant B lymphocytes that have a mature appearance infiltrate in to lymph node,bone marrow,liver and spleen.The 56th American Society of Hematology (ASH) annual meeting explored multiple aspects including pathogenesis,treatment,response evaluation and prognosis of CLL.Clinical outcome of CLL patients can be predicted more accurately by a series of novel markers such as minimal residual disease.The progress of response evaluation and prognosis in CLL were focused in this review.

Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous and aggressive non-Hodgkin's lymphoma with poor prognosis under current treatment algorithm.Reports on treatment of PTCL in the 56th American Society of Hematology (ASH) annual meeting cover comprehensive aspects,among which exploration of effective low-toxicity treatment strategies for patients with PTCL is coming into the focus of this meeting.THP-COP regimen,romidepsin,bortezomib alone or in combination with panobinostat,brentuximab vedotin and stem cell transplantation provide more attractive options for both untreated and refractory/relapsed patients with PTCL,while novel drugs including Duvelisib (IPI-145),crizotinib and antiPD-1 antibody offer new hope for patients with PTCL.